WINIMED 50 DEUS MEDICAL

£57.00

WINIMED 50 DEUS MEDICAL contains stanozolol for advanced research into anabolic compound mechanisms and performance enhancement pathways in laboratory settings.

 

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
WINIMED 50 DEUS MEDICAL
WINIMED 50 DEUS MEDICAL
£57.00

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Research Overview: WINIMED 50 DEUS MEDICAL

WINIMED 50 DEUS MEDICAL is a pharmaceutical-grade stanozolol preparation designed for comprehensive laboratory investigations into anabolic steroid mechanisms and cellular response pathways. This research compound enables scientists to study the molecular interactions of stanozolol with androgen receptors and examine its effects on protein synthesis pathways in controlled experimental environments. As a leading UK supplier, Stroid UK Shop provides researchers with access to this high-purity compound for detailed in-vitro studies examining anabolic processes.

Laboratory Research Applications

Research teams utilise WINIMED 50 to investigate stanozolol’s binding affinity to androgen receptors and analyse its impact on cellular protein synthesis mechanisms. Studies focus on examining the compound’s molecular structure and its interaction with various cellular pathways involved in anabolic processes. Scientists frequently compare stanozolol research outcomes with other compounds available in our stanozolol category, alongside investigations involving SARMs compounds and research peptides to understand comparative molecular mechanisms and cellular responses in controlled laboratory conditions.

Technical Specifications

WINIMED 50 DEUS MEDICAL Research Specifications
Parameter Specification
Active Compound Stanozolol
Concentration 50mg per tablet
Manufacturer Deus Medical
Form Oral tablets
CAS Number Verify with supplier
Molecular Formula Verify with supplier
Storage Cool, dry conditions
Purity Pharmaceutical grade

Research Compliance Information

WINIMED 50 DEUS MEDICAL is manufactured exclusively for in-vitro research applications and laboratory studies. This compound is not intended for human consumption, therapeutic use, or any application outside controlled research environments. Researchers must ensure proper laboratory protocols, safety measures, and regulatory compliance when conducting studies with this stanozolol preparation. All research should be conducted by qualified personnel in appropriate laboratory facilities equipped for handling pharmaceutical research compounds safely and effectively.

Related